دورية أكاديمية
Prognostic value for incidental antihypertensive therapy with β-blockers in metastatic colorectal cancer
| العنوان: | Prognostic value for incidental antihypertensive therapy with β-blockers in metastatic colorectal cancer |
|---|---|
| المؤلفون: | Giampieri, R, Del Prete, M, Faloppi, L, Bianconi, M, Ridolfi, F, Cascinu, S., SCARTOZZI, MARIO |
| المساهمون: | Giampieri, R, Scartozzi, Mario, Del Prete, M, Faloppi, L, Bianconi, M, Ridolfi, F, Cascinu, S. |
| سنة النشر: | 2015 |
| المجموعة: | Università degli Studi di Cagliari: UNICA IRIS |
| مصطلحات موضوعية: | Adrenergic beta-Antagonists, Adult, Age factors, Aged, Aged 80 and over, Antibodies, Monoclonal, Humanized, Antihypertensive agents, Antineoplastic combined chemotherapy protocols, Colorectal neoplasms, Disease-free survival, Female, Humans, Hypertension, Kaplan-Meier estimate, Male, Middle aged, Neoplasm metastasis, Prognosis, Prospective studies, Sex factors |
| الوصف: | Previous studies suggested that the incidental use of β-blockers might influence clinical outcome in solid tumors. We assessed the correlation between the incidental use of β-blockers and clinical outcome in colorectal cancer patients treated with first-line chemotherapy alone or in combination with bevacizumab in metastatic colorectal cancer patients. We collected data from 235 metastatic colorectal cancer patients treated with first-line chemotherapy alone (128 patients) or with bevacizumab (107 patients). Patients were stratified for clinical factors such as β-blockers use, age, sex, and site of metastases, previous adjuvant chemotherapy and ECOG performance status. In the chemotherapy alone group patients receiving β-blockers showed an improved overall survival (median OS 41.3 vs 25.7 months, P = 0.03, HR: 2.26, 95% CI: 1.05-3.24). A significant relationship with improved response rate was also evident for B-blocker users (P = 0.044). On the contrary in the β-blockers users group treated with chemotherapy in combination with bevacizumab we observed a trend toward a worse overall survival although nonstatistically significant (median OS 18.5 vs 23.6 months, HR: 0. 89, 95% CI: 0.38-2.03, P = 0.77). Our analysis confirmed a potential prognostic role for the use of β-blockers in colorectal cancer patients treated with chemotherapy. Our findings also suggest a potential worse outcome for patients on β-blockers receiving bevacizumab. Future prospective studies should include the incidental use of β-blockers as stratification factor for clinical outcome. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26091452; info:eu-repo/semantics/altIdentifier/wos/WOS:000360798700001; volume:94; issue:24; firstpage:e719; numberofpages:5; journal:MEDICINE; http://hdl.handle.net/11584/121952Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84941368953 |
| DOI: | 10.1097/MD.0000000000000719 |
| الإتاحة: | https://doi.org/10.1097/MD.0000000000000719Test http://hdl.handle.net/11584/121952Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5943B6E0 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/MD.0000000000000719 |
|---|